These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 25511563)

  • 1. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
    Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
    Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
    Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
    Drug Dev Ind Pharm; 2018 Jan; 44(1):13-18. PubMed ID: 28832225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional ZnPc-loaded mesoporous silica nanoparticles for enhancement of photodynamic therapy efficacy by endolysosomal escape.
    Tu J; Wang T; Shi W; Wu G; Tian X; Wang Y; Ge D; Ren L
    Biomaterials; 2012 Nov; 33(31):7903-14. PubMed ID: 22840227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: in vitro and in vivo studies.
    Ansari L; Jaafari MR; Bastami TR; Malaekeh-Nikouei B
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):594-606. PubMed ID: 29688064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced theranostic efficacy of epirubicin-loaded SPION@MSN through co-delivery of an anti-miR-21-expressing plasmid and ZIF-8 hybridization to target colon adenocarcinoma.
    Abrishami A; Bahrami AR; Saljooghi AS; Matin MM
    Nanoscale; 2024 Mar; 16(12):6215-6240. PubMed ID: 38446130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted modulation of cell differentiation in distinct regions of the gastrointestinal tract via oral administration of differently PEG-PEI functionalized mesoporous silica nanoparticles.
    Desai D; Prabhakar N; Mamaeva V; Karaman DŞ; Lähdeniemi IA; Sahlgren C; Rosenholm JM; Toivola DM
    Int J Nanomedicine; 2016; 11():299-313. PubMed ID: 26855569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
    Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L
    Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of surface modification and size on oral drug delivery of mesoporous silica formulation.
    Wang Y; Cui Y; Zhao Y; Zhao Q; He B; Zhang Q; Wang S
    J Colloid Interface Sci; 2018 Mar; 513():736-747. PubMed ID: 29220688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ofloxacin@Doxorubicin-Epirubicin functionalized MCM-41 mesoporous silica-based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections.
    Galhano J; Marcelo GA; Duarte MP; Oliveira E
    Bioorg Chem; 2022 Jan; 118():105470. PubMed ID: 34814085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The properties of mesoporous silica nanoparticles functionalized with different PEG-chain length via the disulfide bond linker and drug release in glutathione medium.
    Xie Z; Gong H; Liu M; Zhu H; Sun H
    J Biomater Sci Polym Ed; 2016; 27(1):55-68. PubMed ID: 26540096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for the breast cancer therapy.
    Ma'mani L; Nikzad S; Kheiri-Manjili H; Al-Musawi S; Saeedi M; Askarlou S; Foroumadi A; Shafiee A
    Eur J Med Chem; 2014 Aug; 83():646-54. PubMed ID: 25014638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organosilane and Polyethylene Glycol Functionalized Magnetic Mesoporous Silica Nanoparticles as Carriers for CpG Immunotherapy In Vitro and In Vivo.
    Zheng H; Wen S; Zhang Y; Sun Z
    PLoS One; 2015; 10(10):e0140265. PubMed ID: 26451735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
    Zhang Q; Zhao H; Li D; Liu L; Du S
    Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Effects of Polymer-Surface Decoration on Drug Delivery, Cellular Retention, and Action Mechanisms of Functionalized Mesoporous Silica Nanoparticles.
    You Y; Hu H; He L; Chen T
    Chem Asian J; 2015 Dec; 10(12):2744-54. PubMed ID: 26248202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
    Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
    Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
    Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox-responsive mesoporous silica as carriers for controlled drug delivery: a comparative study based on silica and PEG gatekeepers.
    Wang Y; Han N; Zhao Q; Bai L; Li J; Jiang T; Wang S
    Eur J Pharm Sci; 2015 May; 72():12-20. PubMed ID: 25701727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
    Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
    Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy.
    Chang D; Gao Y; Wang L; Liu G; Chen Y; Wang T; Tao W; Mei L; Huang L; Zeng X
    J Colloid Interface Sci; 2016 Feb; 463():279-87. PubMed ID: 26550786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.